問卷

TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Hematology & Oncology

Division of Infectious Disease

Division of Others-

Division of General Internal Medicine

Taipei Veterans General Hospital (在職)

Division of Hematology & Oncology

National Taiwan University Cancer Center (在職)

Division of Hematology & Oncology

National Taiwan University Hospital Hsin-Chu Branch

Division of Hematology & Oncology

更新時間:2023-09-19

柯博升-, -
  • Principal Investigator
  • Clinical Trial Experience (year) 13 years

篩選

List

157Cases

2017-02-10 - 2020-01-30

Phase III

A Randomized, Double-Blind Phase 3 Study of Ibrutinib in Combination With Corticosteroids Versus Placebo in Combination With Corticosteroids in Subjects With New Onset Chronic Graft Versus Host Disease (cGVHD)
  • Condition/Disease

    Chronic Graft Versus Host Disease (cGVHD)

  • Test Drug

    Imbruvica®

Participate Sites
3Sites

Terminated2Sites

2016-01-01 - 2020-03-31

Phase IV

A Multi-Center, Open-Labelled, Pralatrexate Study in Asian Patients with Peripheral T-cell Lymphoma after Prior Therapy
  • Condition/Disease

    Peripheral T-cell Lymphoma

  • Test Drug

    FOLOTYN Solution for intravenous injection

Participate Sites
11Sites

Terminated11Sites

2013-01-15 - 2018-01-30

Phase III

A Phase 3 Randomized, Open-Label Study of Ponatinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
  • Condition/Disease

    Chronic Myeloid Leukemia

  • Test Drug

    AP24534

Participate Sites
3Sites

Terminated2Sites

Study ended1Sites

2016-07-01 - 2018-05-03

Phase I

An open label, phase I trial of intravenous administration of volasertib as monotherapy or in combination with azacitidine in patients with myelodysplastic syndrome after hypomethylating agents treatment failure
  • Condition/Disease

    myelodysplastic syndrome, MDS

  • Test Drug

    Volasertib

Participate Sites
3Sites

Terminated2Sites

2012-12-13 - 2016-10-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2010-09-01 - 2011-09-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2012-08-01 - 2018-10-25

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Study ended4Sites